ORIGINAL ARTICLE
NEUROPLASTICITY AFTER COCHLEAR IMPLANTATION AS ASSESSED BY THE PLASMA LEVEL OF MMP-9 AND ITS GENETIC POLYMORPHISMS: A PROSPECTIVE STUDY OF CONGENITALLY DEAF CHILDREN
,
 
,
 
Monika Ołdak 2, C-E
,
 
,
 
Leszek Kaczmarek 3, A,D,G
,
 
 
 
More details
Hide details
1
Oto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Hearing, Warsaw, Poland
 
2
Department of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland
 
3
Laboratory of Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland
 
 
A - Research concept and design; B - Collection and/or assembly of data; C - Data analysis and interpretation; D - Writing the article; E - Critical revision of the article; F - Final approval of article;
 
 
Submission date: 2022-05-18
 
 
Final revision date: 2022-08-05
 
 
Acceptance date: 2022-08-30
 
 
Publication date: 2022-09-30
 
 
Corresponding author
Monika Matusiak   

Oto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Hearing, Mochanckiego 10, 02-042, Warsaw, Poland
 
 
J Hear Sci 2022;12(3):47-53
 
KEYWORDS
TOPICS
ABSTRACT
Background:
If it was possible to assay biomarkers of neuroplasticity it might facilitate clinical management of deaf implanted children by identifying those among them who are at risk of speech and language rehabilitation failure. MMP9 is a proteinase involved in neuroplasticity underlying different clinical conditions in human.

Material and methods:
This was a longitudinal, prospective cohort study of 61 congenitally deaf children who underwent cochlear implantation. We investigated the genetic variants of matrix metalloproteinase 9 (MMP9) and plasma levels of MMP-9 that have been implicated in neuroplasticity after cochlear implantation. Auditory development was assessed by using the LittlEARS Questionnaire (LEAQ) at three follow-up points and the plasma level of MMP-9 was measured at implantation.

Results:
There was a significant negative correlation between MMP-9 plasma level at implantation and LEAQ score at 18 months follow-up (p < 0.05). Two clusters of good and poor CI performers could be isolated based on this correlation. The prevalence of genetic variants of MMP9 – rs3918242, rs20544, and rs2234681 – in the good performers cluster was different to their prevalence in the poor performers cluster.

Conclusions:
The study showed that children born deaf who have an MMP-9 plasma level of less than 150 ng/ml at cochlear implantation have a reasonable chance of attaining a high LEAQ score after 18 months of speech and language rehabilitation. It appears that MMP-9 plasma level at cochlear implantation is a promising prognostic marker for CI outcome.

Journals System - logo
Scroll to top